All Names: Cosentyx ,Scapho,Secukinumab
Indications:1. Plaque Psoriasis; 2. Psoriatic Arthritis; 3. Ankylosing Spondylitis; 4. Non-Radiographic Axial Spondyloarthritis
Manufacturer:Novartis, Switzerland
Customs Clearance Procedure:If the customs requires the package for customs clearance, please pay the customs clearance fee according to the content of EMS SMS and customs regulations.
INDICATIONS AND USAGE(适应症)
Plaque Psoriasis
COSENTYX® is indicated for the treatment of moderate to severe plaque psoriasis in patients 6 years and older who are candidates for systemic therapy or phototherapy.
Psoriatic Arthritis
COSENTYX is indicated for the treatment of adult patients with active psoriatic arthritis.
Ankylosing Spondylitis
COSENTYX is indicated for the treatment of adult patients with active ankylosing spondylitis.
Non-Radiographic Axial Spondyloarthritis
COSENTYX is indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation.
DOSAGE(服用剂量)
Plaque Psoriasis
Adults
The recommended dosage is 300 mg by subcutaneous injection at Weeks 0, 1, 2, 3, and 4 followed by 300 mg every 4 weeks. Each 300 mg dosage is given as 2 subcutaneous injections of 150 mg.
For some patients, a dose of 150 mg may be acceptable.
Pediatric Patients
The recommended dosage for pediatric patients 6 years of age and older is based on body weight and administered by subcutaneous injection at Weeks 0, 1, 2, 3, and 4 followed by dosing every 4 weeks.
Psoriatic Arthritis
For psoriatic arthritis patients with coexistent moderate to severe plaque psoriasis, use the dosing and administration recommendations for plaque psoriasis.
For other psoriatic arthritis patients, administer COSENTYX with or without a loading dosage by subcutaneous injection. The recommended dosage:
With a loading dosage is 150 mg at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter
Without a loading dosage is 150 mg every 4 weeks
If a patient continues to have active psoriatic arthritis, consider a dosage of 300 mg every 4 weeks.
COSENTYX may be administered with or without methotrexate.
Ankylosing Spondylitis
Administer COSENTYX with or without a loading dosage by subcutaneous injection. The recommended dosage:
With a loading dosage is 150 mg at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter
Without a loading dosage is 150 mg every 4 weeks
If a patient continues to have active ankylosing spondylitis, consider a dosage of 300 mg every 4 weeks.
Non-Radiographic Axial Spondyloarthritis
Administer COSENTYX with or without a loading dosage by subcutaneous injection. The recommended dosage:
With a loading dosage is 150 mg at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter
Without a loading dosage is 150 mg every 4 weeks.
ADVERSE REACTIONS(不良反应)
Infections
Inflammatory Bowel Disease
Hypersensitivity Reactions
For full information, please refer to:
https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/77c4b13e-7df3-42d4-81db-3d0cddb7f67a/spl-doc?hl=Cosentyx
ScaPhoinformation
No information yet!!!